Quantification of Radiation Injury on Neutropenia and the Link between Absolute Neutrophil Count Time Course and Overall Survival in Nonhuman Primates Treated with G-CSF.
Acute radiation syndrome
filgrastim
neutropenia
overall survival
pegfilgrastim
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
10
10
2019
accepted:
02
05
2020
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
16
3
2021
Statut:
epublish
Résumé
To model absolute neutrophil count (ANC) suppression in response to acute radiation (AR) exposure and evaluate ANC time course as a predictor of overall survival (OS) in response to AR exposure with or without treatment with granulocyte colony-stimulating factor in nonhuman primates. Source data were obtained from two pivotal studies conducted in rhesus macaques exposed to 750 cGy of whole body irradiation on day 0 that received either placebo, daily filgrastim, or pegfilgrastim (days 1 and 8 after irradiation). Animals were observed for 60 days with ANC measured every 1 to 2 days. The population model of ANC response to AR and the link between observed ANC time course and OS consisted of three submodels characterizing injury due to radiation, granulopoiesis, and a time-to-event model of OS. The ANC response model accurately described the effects of AR exposure on the duration of neutropenia. ANC was a valid surrogate for survival because it explained 76% (95% CI, 41%-97%) and 73.2% (95% CI, 38.7%-99.9%) of the treatment effect for filgrastim and pegfilgrastim, respectively. The current model linking radiation injury to neutropenia and ANC time course to OS can be used as a basis for translating these effects to humans.
Identifiants
pubmed: 32440783
doi: 10.1007/s11095-020-02839-3
pii: 10.1007/s11095-020-02839-3
pmc: PMC7242243
doi:
Substances chimiques
pegfilgrastim
3A58010674
Polyethylene Glycols
3WJQ0SDW1A
Filgrastim
PVI5M0M1GW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102Subventions
Organisme : Amgen Inc.
ID : Not applicable
Références
Radiat Res. 2013 Jan;179(1):89-100
pubmed: 23210705
Drug Metab Rev. 1996 Nov;28(4):625-58
pubmed: 8959393
Clin Transl Sci. 2020 Jul;13(4):807-817
pubmed: 32112517
Ann Oncol. 2003 Jan;14(1):29-35
pubmed: 12488289
J Immunol. 2018 Jun 15;200(12):4059-4067
pubmed: 29728510
Radiat Res. 2015 Jun;183(6):643-55
pubmed: 26035709
Blood. 1992 Jun 1;79(11):2849-54
pubmed: 1375115
Radiat Res. 2012 Nov;178(5):403-13
pubmed: 22991919
Br J Haematol. 1985 Dec;61(4):675-85
pubmed: 4084457
J Clin Oncol. 2010 Mar 10;28(8):1329-36
pubmed: 20142595
J Clin Oncol. 2002 Feb 1;20(3):727-31
pubmed: 11821454
Blood. 2010 Jul 29;116(4):625-7
pubmed: 20410504
Biometrics. 2004 Jun;60(2):451-60
pubmed: 15180671
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
pubmed: 16023764
J Clin Oncol. 2000 Jul;18(13):2522-8
pubmed: 10893282
Blood. 2016 Jun 30;127(26):3431-8
pubmed: 27136946
Br J Clin Pharmacol. 2018 May;84(5):911-925
pubmed: 29318653
Pharm Res. 1998 May;15(5):690-7
pubmed: 9619776
J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):57-85
pubmed: 17051439
BMC Med. 2011 Nov 25;9:126
pubmed: 22114866